Accolade (ACCD) Stock Forecast & Price Target

Compare

448 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACCD Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Accolade

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACCD Stock 12 Month Forecast

Average Price Target

$7.03

▲(0.14% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $7.03 with a high forecast of $7.03 and a low forecast of $7.03. The average price target represents a 0.14% change from the last price of $7.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","7":"$7","12":"$12","4.5":"$4.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4.5,7,9.5,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Apr<br/>2025","25":"Apr<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.99,6.993076923076924,6.996153846153846,6.99923076923077,7.002307692307692,7.0053846153846155,7.008461538461539,7.0115384615384615,7.014615384615385,7.017692307692308,7.020769230769231,7.023846153846154,7.026923076923077,{"y":7.03,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.99,6.993076923076924,6.996153846153846,6.99923076923077,7.002307692307692,7.0053846153846155,7.008461538461539,7.0115384615384615,7.014615384615385,7.017692307692308,7.020769230769231,7.023846153846154,7.026923076923077,{"y":7.03,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.99,6.993076923076924,6.996153846153846,6.99923076923077,7.002307692307692,7.0053846153846155,7.008461538461539,7.0115384615384615,7.014615384615385,7.017692307692308,7.020769230769231,7.023846153846154,7.026923076923077,{"y":7.03,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.73,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.13,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.03

Average Price Target$7.03

Lowest Price Target$7.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Downgraded

03/05/25

David Larsen

BTIG

―

Hold

―

Assigned

01/10/25

Hold Rating on Accolade: Evaluating Transcarent's Acquisition Amidst Market Challenges

Jeffrey Garro

Stephens

$8→$17

Hold

142.17%

Upside

Downgraded

01/10/25

Accolade downgraded to Equal Weight from Overweight at StephensAccolade downgraded to Equal Weight from Overweight at Stephens

John Ransom

Raymond James

―

Hold

―

Downgraded

01/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Accolade (NASDAQ: ACCD)

David Grossman

Stifel Nicolaus

$8→$7.03

Hold

0.14%

Upside

Downgraded

01/09/25

Accolade downgraded to Hold from Buy at StifelAccolade downgraded to Hold from Buy at Stifel

Richard Close

Canaccord Genuity

$7.03

Hold

0.14%

Upside

Downgraded

01/08/25

Accolade downgraded to Hold from Buy at CanaccordAccolade downgraded to Hold from Buy at Canaccord

Ryan MacDonald

Needham

―

Hold

―

Downgraded

01/08/25

Accolade (ACCD) was downgraded to a Hold Rating at Needham

Michael Cherny

Leerink Partners

$9.5→$7.03

Hold

0.14%

Upside

Downgraded

01/08/25

Accolade downgraded to Market Perform from Outperform at LeerinkAccolade downgraded to Market Perform from Outperform at Leerink

Stan Berenshteyn

Wells Fargo

Hold

-0.28%

Downside

Assigned

01/08/25

Accolade (ACCD) Receives a Hold from Wells Fargo

Craig Hettenbach

Morgan Stanley

$6→$5

Hold

-28.77%

Downside

Reiterated

12/17/24

Morgan Stanley Keeps Their Hold Rating on Accolade (ACCD)

Stephanie Davis

Barclays

Hold

-28.77%

Downside

Reiterated

10/09/24

Accolade (ACCD) Maintains Hold Rating Amid Solid Performance and Cautious Market Outlook

Allen Lutz

Bank of America Securities

$5.75

Buy

-18.09%

Downside

Reiterated

10/08/24

Accolade price target lowered to $5.75 from $7 at BofAAccolade price target lowered to $5.75 from $7 at BofA

Gil Luria

D.A. Davidson

―

Hold

―

Assigned

09/16/24

D.A. Davidson Sticks to Their Hold Rating for Accolade (ACCD)

Jack Wallace

Guggenheim

$13→$6

Buy

-14.53%

Downside

Reiterated

06/28/24

Accolade price target lowered to $6 from $13 at GuggenheimAccolade price target lowered to $6 from $13 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Downgraded

03/05/25

David Larsen

BTIG

―

Hold

―

Assigned

01/10/25

Hold Rating on Accolade: Evaluating Transcarent's Acquisition Amidst Market Challenges

Jeffrey Garro

Stephens

$8→$17

Hold

142.17%

Upside

Downgraded

01/10/25

Accolade downgraded to Equal Weight from Overweight at StephensAccolade downgraded to Equal Weight from Overweight at Stephens

John Ransom

Raymond James

―

Hold

―

Downgraded

01/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (NASDAQ: MLTX) and Accolade (NASDAQ: ACCD)

David Grossman

Stifel Nicolaus

$8→$7.03

Hold

0.14%

Upside

Downgraded

01/09/25

Accolade downgraded to Hold from Buy at StifelAccolade downgraded to Hold from Buy at Stifel

Richard Close

Canaccord Genuity

$7.03

Hold

0.14%

Upside

Downgraded

01/08/25

Accolade downgraded to Hold from Buy at CanaccordAccolade downgraded to Hold from Buy at Canaccord

Ryan MacDonald

Needham

―

Hold

―

Downgraded

01/08/25

Accolade (ACCD) was downgraded to a Hold Rating at Needham

Michael Cherny

Leerink Partners

$9.5→$7.03

Hold

0.14%

Upside

Downgraded

01/08/25

Accolade downgraded to Market Perform from Outperform at LeerinkAccolade downgraded to Market Perform from Outperform at Leerink

Stan Berenshteyn

Wells Fargo

Hold

-0.28%

Downside

Assigned

01/08/25

Accolade (ACCD) Receives a Hold from Wells Fargo

Craig Hettenbach

Morgan Stanley

$6→$5

Hold

-28.77%

Downside

Reiterated

12/17/24

Morgan Stanley Keeps Their Hold Rating on Accolade (ACCD)

Stephanie Davis

Barclays

Hold

-28.77%

Downside

Reiterated

10/09/24

Accolade (ACCD) Maintains Hold Rating Amid Solid Performance and Cautious Market Outlook

Allen Lutz

Bank of America Securities

$5.75

Buy

-18.09%

Downside

Reiterated

10/08/24

Accolade price target lowered to $5.75 from $7 at BofAAccolade price target lowered to $5.75 from $7 at BofA

Gil Luria

D.A. Davidson

―

Hold

―

Assigned

09/16/24

D.A. Davidson Sticks to Their Hold Rating for Accolade (ACCD)

Jack Wallace

Guggenheim

$13→$6

Buy

-14.53%

Downside

Reiterated

06/28/24

Accolade price target lowered to $6 from $13 at GuggenheimAccolade price target lowered to $6 from $13 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Accolade

Which Analyst Should I Follow If I Want to Buy ACCD and Sell After:

1 Month

xxx

Success Rate

2/5 ratings generated profit

Average Return

-4.54%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -4.54% per trade.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+19.00%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +19.00% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

4/5 ratings generated profit

Average Return

+58.12%

reiterated a buy rating 7 months ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +58.12% per trade.

2 Years

xxx

Success Rate

4/5 ratings generated profit

Average Return

+64.82%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +64.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACCD Analyst Recommendation Trends

Rating

Dec 24

Jan 25

Feb 25

Mar 25

Apr 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACCD has received 0 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ACCD average Analyst price target in the past 3 months is 7.03.

Each month's total comprises the sum of three months' worth of ratings.

ACCD Financial Forecast

ACCD Earnings Forecast

Next quarter’s earnings estimate for ACCD is $0.04 with a range of -$0.01 to $0.08. The previous quarter’s EPS was -$1.50. ACCD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.60% of the time in the same period. In the last calendar year ACCD has Outperformed its overall industry.

ACCD Sales Forecast

Next quarter’s sales forecast for ACCD is $145.16M with a range of $144.80M to $145.50M. The previous quarter’s sales results were $105.06M. ACCD beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.95% of the time in the same period. In the last calendar year ACCD has Outperformed its overall industry.

ACCD Stock Forecast FAQ

What is ACCD’s average 12-month price target, according to analysts?

Based on analyst ratings, Accolade, Inc.’s 12-month average price target is 7.03.

What is ACCD’s upside potential, based on the analysts’ average price target?

Accolade, Inc. has 0.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACCD a Buy, Sell or Hold?

Accolade, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Accolade, Inc.’s price target?

The average price target for Accolade, Inc. is 7.03. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.03 ,the lowest forecast is $7.03. The average price target represents 0.14% Increase from the current price of $7.02.

What do analysts say about Accolade, Inc.?

Accolade, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of ACCD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Accolade (ACCD) Stock Forecast & Price Target

ACCD Analyst Ratings

ACCD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Accolade

ACCD Analyst Recommendation Trends

ACCD Financial Forecast

ACCD Earnings Forecast

ACCD Sales Forecast

ACCD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts